The renin-angiotensin system in the eye

Experimental Approaches to Diabetic Retinopathy

Volumn 20, Issue , 2009, Pages 142-157

  Ströder, Katja ^a   Unger, Thomas ^a   Steckelings, Ulrike Muscha ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84883218828     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000262667     Document Type: Chapter

References (112)

1. Tigerstedt R, Bergman PG: Niere und Kreislauf. Skand Arch Physiol 1898;8:223-271.
2. Goldblatt H, Lynch J, Hanzal RF: Studies on experimental hypertension. J Exp Med 1934;59:347-379.
3. Braun-Mendenez E, Fasciolo JC, Leloir LF, Munoz JM: The substance causing renal hypertension. J Physiol 1940;98:283-298.
4. Page IH, Helmer OM: A cristalline pressor substance (angiotonin) resulting from the reaction between renin and renin activator. J Exp Med 1940;71:29-42.
5. Braun-Mendénez E, Page IH: Suggested revision of nomenclature: angiotensin. Science 1958;127:242.
6. Skeggs LT, Jr., Marsh WH, Kahn JR, Shumway NP: The existence of two forms of hypertensin. J Exp Med 1954;99:275-282.
7. Ferreira SH, Bartelt DC, Greene LJ: Isolation of bradykinin-potentiating peptides from Bothrops jararaca venom. Biochemistry 1970;9:2583-2593.
8. Mancia G (ed): Angiotensin II Receptor Antagonists. Abingdon, Informa HealthCare, 2006, pp 1-207.
9. Hershey JC, Steiner B, Fischli W, Feuerstein G: Renin inhibitors: An antihypertensive strategy on the verge of reality. Drug Discov Today Ther Strateg 2005;2:181-185.
10. Hernández Prada JA, Ferreira AJ, Katovich MJ, Shenoy V, Qi Y, Santos RA, Castellano RK, Lampkins AJ, Gubala V, Ostrov DA, Raizada MK: Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension 2008;51:1312-1317.
11. Wan Y, Wallinder C, Plouffe B, Beaudry H, Mahalingam AK, Wu X, Johansson B, Holm M, Botoros M, Karlen A, Pettersson A, Nyberg F, Fändriks L, Gallo-Payet N, Hallberg A, Alterman M: Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem 2004;47:5995-6008.
12. Steckelings, UM, Unger, T: The reninangiotensin-aldosterone system; in Mancia G, Grassi G, Kjeldsen S (eds): Manual of Hypertension of The European Society of Hypertension. Abingdon, Informa HealthCare, 2008, vol 14, pp 110-116.
13. Jaspard E, Costerousse O, Wei L, Corvol P, Alhenc-Gelas F: The angiotensin I-converting enzyme (kinase II): molecular and regulatory aspects. Agents Actions Suppl 1992;38:349-358.
14. Paul M, Poyan Mehr A, Kreutz R: Physiology of local renin-angiotensin systems. Physiol Rev 2006;86:747-803.
15. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T: International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000;52:415-472.
16. Wruck CJ, Funke-Kaiser H, Pufe T, Kusserow H, Menk M, Schefe JH, Kruse ML, Stoll M, Unger T: Regulation of transport of the angiotensin AT2 receptor by a novel membrane-associated Golgi protein. Arterioscler Thromb Vasc Biol 2005;25:57-64.
17. Nouet S, Amzallag N, Li JM, Louis S, Seitz I, Cui TX, Alleaume AM, Di Benedetto M, Boden C, Masson M, Strosberg AD, Horiuchi M, Couraud PO, Nahmias D: Trans-inactivation of receptor tyrosine kinase by novel angiotensin II AT2 receptor-interacting protein, ATIP. J Biol Chem 2004;279:28989-28997.
18. Senbonmatsu T, Saito T, Landon EJ, Watanabe O, Price E, Roberts RL, Imboden H, Fitzgerald TG, Gaffney FA, Inagami T: A novel angiotensin II type 2 receptor signaling pathway: possible role in cardiac hypertrophy. EMBO J 2003;22:6471-6482.
19. Steckelings UM, Kaschina E, Unger T: The AT2 receptor - a matter of love and hate. Peptides 2005;26:1401-1409.
20. Kaschina E, Grzesiak A, Li J, Foryst-Ludwig A, Timm M, Rompe F, Sommerfeld M, Kemnitz R, Curato C, Namsolleck P, Tschöpe C, Hallberg A, Alterman M, Hucko T, Paetsch I, Dietrich T, Schnackenburg B, Graf C, Dahlöf B, Kintscher U, Unger T, Steckelings UM: AT2-receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin-system in myocardial infarction? Circulation 2008;118:2523-2532.
21. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ: A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 2000;275:33238-33243.
22. Ferrario CM, Trask AJ, Jessup JA: Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol 2005;289:H2281-H2290.
23. Burckle C, Bader M: Prorenin and its ancient receptor. Hypertension 2006;48:549-551.
24. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD: Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002;109:1417-1427.
25. Ganten D, Minnich JL, Granger P, Hayduk K, Brecht HM, Barbeau A, Boucher R, Genest J: Angiotensin-forming enzyme in brain tissue. Science 1971;173:64-65.
26. Ikemoto F, Yamamoto K: Renin-angiotensin system in the aqueous of rabbits, dogs and monkeys. Exp Eye Res 1978;27:723-725.
27. Danser AH, van den Dorpel MA, Deinum J, Derkx FH, Franken AA, Peperkamp E, de Jong PT, Schalekamp MA: Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J Clin Endocrinol Metab 1989;68:160-167.
28. Deinum J, Derkx FH, Danser AH, Schalekamp MA: Renin in the bovine eye. J Hypertens Suppl 1989;7:S216-S217.
29. Berka JL, Stubbs AJ, Wang DZ, DiNicolantonio R, Alcorn D, Campbell DJ, Skinner SL: Renin-containing Muller cells of the retina display endocrine features. Invest Ophthalmol Vis Sci 1995;36:1450-1458.
30. Danser AH, Derkx FH, Admiraal PJ, Deinum J, de Jong PT, Schalekamp MA: Angiotensin levels in the eye. Invest Ophthalmol Vis Sci 1994;35:1008-1018.
31. Wagner J, Danser AH, Derkx FH, de Jong TV, Paul M, Mullins JJ, Schalekamp MA, Ganten D: Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular renin-angiotensin system. Br J Ophthalmol 1996;80:159-163.
32. Sarlos S, Wilkinson-Berka JL. The renin-angiotensin system and the developing retinal vasculature. Invest Ophthalmol Vis Sci 2005;46:1069-1077.
33. Sramek SJ, Wallow IH, Day RP, Ehrlich EN: Ocular renin-angiotensin: immunohistochemical evidence for the presence of prorenin in eye tissue. Invest Ophthalmol Vis Sci 1988;29:1749-1752.
34. Sramek SJ, Wallow IH, Tewksbury DA, Brandt CR, Poulsen GL: An ocular renin-angiotensin system. Immunohistochemistry of angiotensinogen. Invest Ophthalmol Vis Sci 1992;33:1627-1632.
35. Vita JB, Anderson JA, Hulem CD, Leopold IH: Angiotensin-converting enzyme activity in ocular fluids. Invest Ophthalmol Vis Sci 1981;20:255-257.
36. Weinreb RN, Sandman R, Ryder MI, Friberg TR: Angiotensin-converting enzyme activity in human aqueous humor. Arch Ophthalmol 1985;103:34-36.
37. Senanayake P, Drazba J, Shadrach K, Milsted A, Rungger-Brandle E, Nishiyama K, Miura S, Karnik S, Sears JE, Hollyfield JG: Angiotensin II and its receptor subtypes in the human retina. Invest Ophthalmol Vis Sci 2007;48:3301-3311.
38. Savaskan E, Loffler KU, Meier F, Muller-Spahn F, Flammer J, Meyer P: Immunohistochemical localization of angiotensin-converting enzyme, angiotensin II and AT1 receptor in human ocular tissues. Ophthalmic Res 2004;36:312-320.
39. Maruichi M, Oku H, Takai S, Muramatsu M, Sugiyama T, Imamura Y, Minami M, Ueki M, Satoh B, Sakaguchi M, Miyazaki M, Ikeda T: Measurement of activities in two different angiotensin II generating systems, chymase and angiotensin-converting enzyme, in the vitreous fluid of vitreoretinal diseases: a possible involvement of chymase in the pathogenesis of macular hole patients. Curr Eye Res 2004;29:321-325.
40. Shiota N, Saegusa Y, Nishimura K, Miyazaki M: Angiotensin II-generating system in dog and monkey ocular tissues. Clin Exp Pharmacol Physiol 1997;24:243-248.
41. Geng L, Persson K, Nilsson SF: Angiotensin converting anzyme (ACE) activity in porcine ocular tissue: effects of diet and ACE inhibitors. J Ocul Pharmacol Ther 2003;19:589-598.
42. Tikellis C, Johnston CI, Forbes JM, Burns WC, Thomas MC, Lew RA, Yarski M, Smith AI, Cooper ME. Identification of angiotensin converting enzyme 2 in the rodent retina. Curr Eye Res 2004;29:419-427.
43. Price DA, Porter LE, Gordon M, Fisher NDL, De'Oliviera JMF, Laffel LMB, Passan DR, Williams GH, Hollenberg NK: The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol 1999;10:2382-2391.
44. Franken AA, Derkx FH, Schalekamp MA, Man int'Veld AJ, Hop WC, van Rens EH, de Jong PT: Association of high plasma prorenin with diabetic retinopathy. J Hypertens Suppl 1988;6:S461-S463.
45. Yokota H, Mori F, Kai K, Nagaoka T, Izumi N, Takahashi A, Nikichi T, Yoshida A, Suzuki F, Ishida Y: Serum prorenin levels and diabetic retinopathy in type 2 diabetes: new method to measure serum level of prorenin using antibody activating direct kinetic assay. Br J Ophthalmol 2005;89:871-873.
46. Wilkinson-Berka JL: Angiotensin and diabetic retinopathy. Int J Biochem Cell Biol 2006;38:752-765.
47. Carey RM, Siragy HM: The intrarenal renin-angiotensin system and diabetic nephropathy. Trends Endocrinol Metab 2003;14:274-281.
48. Ebrahimian TG, Tamarat R, Clergue M, Duriez M, Levy BI, Silvestre JS: Dual effect of angiotensin-converting enzyme inhibition on angiogenesis in type 1 diabetic mice. Arterioscler Thromb Vasc Biol 2005;25:65-70.
49. Funatsu H, Yamashita H, Ikeda T, Nakanishi Y, Kitano S, Hori S: Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. Am J Ophthalmol 2002;133:537-543.
50. Toma I, Kang JJ, Sipos A, Vargas S, Bansal E, Hanner F, Meer E, Peti-Peterdi J: Succinate receptor GPR91 provides a direct link between high glucose levels and renin release in murine and rabbit kidney. J Clin Invest 2008;118:2526-2534.
51. Sapieha P, Sirinyan M, Hamel D, Zaniolo K, Joyal J-S, Cho J-H, Honoré J-C, Kermorvant-Duchemin E, Varma DR, Tremblay S, Leduc M, Rihakova L, Hardy P, Klein WH, Mu X, Mamer O, Lachapelle P, Di Polo A, Beauséjour C, Andelfinger G, Mitchell G, Sennlaub F, Chemtob S: The succinate receptor GPR91 in neurons has a major role in retinal angiogenesis. Nat Med 2008;14:1067-1076.
52. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-820.
53. Brownlee M: Banting lecture 2004. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54:1615-1625.
54. Ellis EA, Grant MB, Murray FT, Wachowski MB, Guberski DL, Kubilis PS, Lutty GA: Increased NADH oxidase activity in the retina of the BBZ/Wor diabetic rat. Free Rad Biol Med 1998;24:111-201.
55. Förstermann U: Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat Clin Pract Cardiovasc Med 2008;5:338-349.
56. Yamagishi S, Amano S, Inagaki Y, Okamoto T, Inoue H, Takeuchi M, Choei H, Sasaki N, Kikuchi S: Angiotensin IItype receptor interaction upregulates vascular endothelial growth factor messenger RNA levels in retinal pericytes through intracellular reactive oxygen species generation. Drugs Exp Clin Res 2003;29:75-80.
57. Kawamura H, Kobayashi M, Li Q, Yamanishi S, Katsumura K, Minami M, Wu DM, Puro DG: Effects of angiotensin II on the pericyte-containing microvasculature of the rat retina. J Physiol 2004;561:671-683.
58. Ruiz-Ortega M, Lorenzo O, Egido, J: Angiotensin II increases monocytic chemotactic protein-1 and activates nuclear transcription factor κB and activator protein-1 in cultured mesangial and mononuclear cells. Kidney Int 2000;57:2285-2298.
59. Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, Griendling KK: Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ Res 2002;91:406-413.
60. Kato H, Suzuki H, Tajima S, Ogata Y, Tominaga T, Sato A, Saruta T: Angiotensin II stimulates collagen synthesis in cultured vascular smooth muscle cells. J Hypertens 1991;9:17-22.
61. Thomas MC, Tikellis C, Burns WM, Bialkowski K, Cao Z, Coughlan MT, Jandeleit-Dahm K, Cooper ME, Forbes JM: Interactions between renin angiotensin system and advanced glycation in the kidney. J Am Soc Nephrol 2005;16:2976-2984.
62. Clements RS Jr, Morrison AD, Winegrad AI: Polyol pathway in aorta: regulation by hormones. Science 1969;166:1007-1008.
63. Xu X, Zhu Q, Xia X, Zhang S, Gu Q, Luo D: Blood-retinal barrier breakdown induced by activation of protein kinase C via vascular endothelial growth factor in streptozotocin-induced diabetic rats. Curr Eye Res 2004;28:251-256.
64. Otani A, Takagi H, Oh H, Koyama S, Honda Y: Angiotensin II induces expression of the Tie2 receptor ligand, angiopoietin-2, in bovine retinal endothelial cells. Diabetes 2001;50:867-875.
65. Policha A, Daneshtalab N, Chen L, Dale LB, Altier C, Khosravani H, Thomas WG, Zamponi GW, Ferguson SSG: Role of angiotensin II type 1A receptor phosphorylation, phospholipase D, and extracellular calcium in isoform-specific protein kinase C membrane translocation responses. J Biol Chem 2006;281:26340-26349.
66. Williams B, Gallacher B, Patel H, Orme D: Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro. Diabetes 1997;46:1497-1503.
67. Yokota T, Ma RC, Park J-Y, Isshiki K, Sotiropoulos KB, Rauniyar RK, Bornfeldt KE, King GL: Role of protein kinase C on the expression of plateletderived growth factor and endothelin-1 in the retina of diabetic rats and cultured retinal capillary pericytes. Diabetes 2003;52:838-845.
68. Feener EP, Xia P, Inoguchi T, Shiba T, Kunisaki M, King GL: Role of protein kinase C in glucose- and angiotensin II-induced plasminogen activator inhibitor expression. Contrib Nephrol 1996;118:180-187.
69. Koya D, Jirousek MR, Lin YW, Ishii H, Kuboki K, King GL: Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest 1997;100:115-126.
70. Kuboki K, Jiang ZY, Takahara N, Ha SW, Igarashi M, Yamauchi T, Feener EP, Herbert TP, Rhodes CJ, King GL: Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation 2000;101:676-681.
71. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, Bursell SE, Kern TS, Ballas LM, Heath WF, Stramm LE, Feener EP, King GL: Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996;272:728-731.
72. Yerneni KK, Bai W, Khan BV, Medford RM, Natarajan R: Hyperglycemiainduced activation of nuclear transcription factor kappaB in vascular smooth muscle cells. Diabetes 1999;48:855-864.
73. Nagai N, Izumi-Nagai K, Oike Y, Koto T, Satofuka S, Ozawa Y, Yamashiro K, Inoue M, Tsubota K, Umezawa K, Ishida S: Suppression of diabetesinduced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway. Invest Ophthalmol Vis Sci 2007;48:4342-4350.
74. Gabriely I, Yang XM, Cases JA, Ma XH, Rossetti L, Barzilai N: Hyperglycemia modulates angiotensinogen gene expression. Am J Physiol Regul Integr Comp Physiol 2001;281:795-802.
75. Hsieh TJ, Fustier P, Zhang SL, Filep JG, Tang SS, Ingelfinger JR, Fantus IG, Hamet P, Chan JS: High glucose stimulates angiotensinogen gene expression and cell hypertrophy via activation of the hexosamine biosynthesis pathway in rat kidney proximal tubular cells. Endocrinology 2003;144:4338-4349.
76. Chen P, Guo AM, Edwards PA, Trick G, Scicli AG: Role of NADPH oxidase and ANG II in diabetes-induced retinal leukostasis. Am J Physiol Regul Integr Comp Physiol 2007;293:1619-1629.
77. Fukumoto M, Takai S, Ishizaki E, Sugiyama T, Oku H, Jin D, Sakaguchi M, Sakonjo H, Ikeda T, Miyazaki M: Involvement of angiotensin II-dependent vascular endothelial growth factor gene expression via NADPH oxidase in the retina in a type 2 diabetic rat model. Curr Eye Res 2008;33:885-891.
78. Banday AA, Lokhandwala MF: Oxidative stress-induced renal angiotensin AT1 receptor upregulation causes increased stimulation of sodium transporters and hypertension. Am J Physiol Renal Physiol 2008;295:698-706.
79. Cheng XW, Murohara T, Kuzuya M, Izawa H, Sasaki T, Obata K, Nagata K, Nishizawa T, Kobayashi M, Yamada T, Kim W, Sato K, Shi GP, Okumura K, Yokota M: Superoxide-dependent cathepsin activation is associated with hypertensive myocardial remodeling and represents a target for angiotensin II type 1 receptor blocker treatment. Am J Pathol 2008;173:358-369.
80. Clermont A, Bursell SE, Feener EP: Role of the angiotensin II type 1 receptor in the pathogenesis of diabetic retinopathy: effects of blood pressure control and beyond. J Hypertens Suppl 2006;24:73-80.
81. Sugiyama T, Okuno T, Fukuhara M, Oku H, Ikeda T, Obayashi H, Ohta M, Fukui M, Hasegawa G, Nakamura N: Angiotensin II receptor blocker inhibits abnormal accumulation of advanced glycation end products and retinal damage in a rat model of type 2 diabetes. Exp Eye Res 2007;85:406-412.
82. Fan Q, Liao J, Kobayashi M, Yamashita M, Gu L, Gohda T, Suzuki Y, Wang LN, Horikoshi S, Tomino Y: Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice. Nephrol Dial Transplant 2004;19:3012-3020.
83. Mori F, Hikichi T, Nagaoka T, Takahashi J, Kitaya N, Yoshida A: Inhibitory effect of losartan, an AT1 angiotensin II receptor antagonist, on increased leucocyte entrapment in retinal microcirculation of diabetic rats. Br J Ophthalmol 2002;86:1172-1174.
84. Malhotra A, Kang BPS, Cheung S, Opawumi D, Meggs LG: Angiotensin II promotes glucose-induced activation of cardiac protein kinase C isozymes and phosphorylation of troponin I. Diabetes 2001;50:1918-1926.
85. Osicka TM, Yu Y, Lee V, Panagiotopoulos S, Kemp BE, Jerums G: Aminoguanidine and ramipril prevent diabetes induced increases in protein kinase C activity in glomeruli, retina and mesenteric artery. Clin Sci 2001;100:249-257.
86. Jesmin S, Sakuma I, Hattori Y, Kitabatake A: Role of angiotensin II in altered expression of molecules responsible for coronary matrix remodeling in insulinresistant diabetic rats. Arterioscler Thromb Vasc Biol 2003;23:2021-2026.
87. Feke GT, Buzney SM, Ogasawara H, Fujio N, Goger DG, Spack NP, Gabbay KH: Retinal circulatory abnormalities in type 1 diabetes. Invest Ophthalmol Vis Sci 1994;35:2968-2975.
88. Das Evcimen N, King GL: The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res 2007;55:498-510.
89. Aiello LP, Clermont AC, Arora V, Davis MD, Sheetz MJ, Bursell S-E: Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Invest Ophthalmol Vis Sci 2006;47:86-92.
90. Horio N, Clermont AC, Abiko A, Abiko T, Shoelson BD, Bursell S-E, Feener EP: Angiotensin AT1 receptor antagonism normalizes retinal blood flow and acetylcholine-induced vasodiliation in normotensive diabetic rats. Diabetologia 2004;47:113-123.
91. Iwase M, Doi Y, Goto D, Ichikawa K, Iino K, Yoshinari M, Fujishima M: Effect of nicardipine versus enalapril on plasma endothelin-1 in hypertensive patients with type 2 diabetes mellitus. Clin Exp Hypertens 2000;22:695-703.
92. Nuwayri-Salti N, Karam CH, Al Jaroudi WA, Usta JA, Maharsy WM, Bitar KM, Bikhazi AB: Effect of type-1 diabetes mellitus on the regulation of insulin and endothelin-1 receptors in rat hearts. Can J Physiol Pharmacol 2007;85:215-224.
93. Liang W, Tan CYR, Ang L, Granville DJ, Wright JM, Laher I: Ramipril improves oxidative stress-related vascular endothelial dysfunction in db/db mice. J Physiol Sci 2008;58:405-411.
94. Gilbert RE, Kelly DJ, Cox AJ, Wilkinson-Berka JL, Rumble JR, Osicka T, Panagiotopoulos S, Lee V, Hendrich EC, Jerums G, Cooper ME: Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. Diabetologia 2000;43:1360-1387.
95. Nagisa Y, A. Shintani, Nakagawa S: The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats Diabetologia. 2001;44:883-888.
96. Moravski CJ, Skinner SL, Stubbs AJ, Sarlos S, Kelly DJ, Cooper ME, Gilbert RE, Wilkinson-Berka JL: The reninangiotensin system influences ocular endothelial cell proliferation in diabetes: transgenic and interventional studies. Am J Pathol 2003;162:151-160.
97. Wilkinson-Berka JL, Tan G, Jaworski K, Ninkovic S: Valsartan but not atenolol improves vascular pathology in diabetic Ren-2 rat retina. Am J Hypertens 2007;20:423-430.
98. Manea A, Constantinescu E, Popov D, Raicu M: Changes in oxidative balance in rat pericytes exposed to diabetic conditions. J Cell Mol Med 2004;8:117-126.
99. Onozato ML, Tojo A, Goto A, Fujita T, Wilcox CS: Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int 2002;61:186-194.
100. Chiarelli F, Di Marzio D, Santilli F, Mohn A, Blasetti A, Cipollone F, Mezzetti A, Verrotti A: Effects of irbesartan on intracellular antioxidant enzyme expression and activity in adolescents and young adults with early diabetic angiopathy. Diab Care 2005;28:1690-1697.
101. Chen S, Ge Y, Si J, Rifai A, Dworkin LD, Gong R: Candesartan suppresses chronic renal inflammation by a novel antioxidant action independent of AT1R blockade. Kidney Int 2008;74:1128-1138.
102. Izuhara Y, Sada T, Yanagisawa H, Koike H, Ohtomo S, Dan T, Ito S, Nangaku M, van Ypersele de Strihou C, Miyata T: A novel sartan derivative with very low angiotensin II type 1 receptor affinity protects the kidney in type 2 diabetic rats. Arterioscler Thromb Vasc Biol 2008;28:1767-1773.
103. Ruilope LM: Angiotensin receptor blockers: RAAS blockade and renoprotection. Curr Med Res Opin 2008;24:1285-1293.
104. American Diabetes Association. Standards of medical care in diabetes - 2008. Diabetes Care 2008;31(suppl 1): S12-S54.
105. UK Prospective Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38, BMJ 1998;317:703-713.
106. Larsen M, Hommel E, Parving HH, Lund-Andersen H: Protective effect of captopril on the blood-retina barrier in normotensive insulin-dependent diabetic patients with nephropathy and background retinopathy, Graefes Arch Clin Exp Ophthalmol 1990;228:505-509.
107. Chase HP, Garg SK, Harris S, Hoops S, Jackson WE, Holmes DL: Angiotensinconverting enzyme inhibitor treatment for young normotensive diabetic subjects: a two-year trial. Ann Ophthalmol 1993;25:284-289.
108. Ravid M, Savin H, Lang R, Jutrin I, Shoshana L, Lishner M: Proteinuria, renal impairment, metabolic control, and blood pressure in type 2 diabetes mellitus. A 14-year follow-up report on patients, Arch Intern Med 1992;152:1225-1229.
109. Chaturvedi N, Sjolie A-K, Stephenson JM, Abrahamian H, Keipes M, Castellarin A, Rogulja-Pepeonik Z, Fuller JH, the EUCLID Study Group: Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998;351:28-31.
110. Sjolie AK: Prospects for angiotensin receptor blockers in diabetic retinopathy. Diab Res Clin Prac 2007;76S: S31-S39.
111. Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, Bilous R, Sjølie AK, for the DIRECT Programme Study Group: Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 2008;372:1394-1402.
112. Sjølie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, Bilous R, Chaturvedi N, for the DIRECT Programme Study Group: Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 2008;372:1385-1393.